Patrick Zweidler-McKay

Company: ImmunoGen

Job title: Executive Director - Medical


Outlining the Phase III Approval of ImmunoGen’s ELAHERE, Lessons Learned & Next Steps 8:30 am

Exploring the rollercoaster journey of ImmunoGen’s Mirvetuximab Soravtansine, which targets folate receptor alpha Emphasizing the importance of designing a clinical trial to enrol the right patients and utilizing biomarker strategies Discussing the next steps for ImmunoGen following this ground-breaking approvalRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.